Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.